About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Colorado | 18,143 Studies Near You | Clareo Health

Clinical Trials LocationsColorado

Clinical Trials in Colorado

Discover 18,143 clinical trials near Colorado. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 7461-7480 of 18,143 trials

TERMINATEDPhase 331 miles

Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

NCT02600429

The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of NK.

Neurotrophic Keratopathy

ReGenTree, LLC18 participantsStarted Sep 2015

Lancaster, California, United States • Colorado Springs, Colorado, United States • Fort Collins, Colorado, United States +8 more locations

COMPLETED48 miles

Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"

NCT04144738

The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test.

Colorectal Cancer

Exact Sciences Corporation26,758 participantsStarted Nov 2019

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +192 more locations

Find Trials by Condition in Colorado

Breast Cancerin Colorado Lung Cancerin Colorado Prostate Cancerin Colorado Colorectal Cancerin Colorado Melanomain Colorado Leukemiain Colorado Lymphomain Colorado Pancreatic Cancerin Colorado Ovarian Cancerin Colorado Brain Cancerin Colorado Diabetes

Data from ClinicalTrials.govTerms

UNKNOWNNA50 miles

Effect of Therapeutic Joint Arthrocentesis on Pain and Quadriceps Function in Patients With Knee Osteoarthritis

NCT04146649

This will be prospective study of patients with knee effusion associated with degenerative osteoarthritis or symptomatic primary total knee arthroplasty that undergo therapeutic joint arthrocentesis. The diagnosis of knee osteoarthritis will be based on knee radiographs (including AP, Rosenburg view, lateral and Merchant views) read and interpreted by one of our clinical providers (PA, Fellow or Surgeon). Patients with at least Grade II Kellgren and Lawrence changes or higher will be included in the osteoarthritis group. Patients in the arthroplasty group must have had a primary total knee arthroplasty without infection (as determined by knee aspirate) to be included. Patients will be clinically evaluated at the time of their visit for presence of a knee effusion using a stroke test and graded on a 5-point scale (zero, trace, 1+, 2+, or 3+) which has shown good interrater reliability. Patients with a mild to severe effusion (1+ to 3+) will considered for the study. Patients having significant pain associated with their effusion will be offered a therapeutic arthrocentesis as part of their treatment plan discussion. This is a pre-post test design in which outcome measures will be collected immediately pre-arthrocentesis and immediately post arthrocentesis. Additionally, there will be an optional 7-10 follow up visit where outcomes measures will be collected again, should the participant choose to return to this visit.

Colorado Joint Replacement66 participantsStarted Dec 2019

Aurora, Colorado, United States • Denver, Colorado, United States

COMPLETED53 miles

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326

Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved. A total of approximately 7000 children aged \<21 years who are receiving these drugs for standard of care will be enrolled and will be followed for up a maximum of 90 days. The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws) this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care. The data collected through this initiative will also provide valuable pharmacokinetic and dosing information of drugs in different pediatric age groups as well as special pediatric populations (i.e. obese).

AdenovirusAnesthesiaAnxiety+56 more

Daniel Benjamin3,520 participantsStarted Nov 2011

Anchorage, Alaska, United States • Little Rock, Arkansas, United States • La Jolla, California, United States +49 more locations

COMPLETEDPhase 3366 miles

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

NCT03737110

The primary objective of this study was to assess the efficacy of rilonacept treatment in participants with recurrent pericarditis.

Recurrent Pericarditis

Kiniksa Pharmaceuticals (UK), Ltd.86 participantsStarted Jan 2019

Los Angeles, California, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +18 more locations

COMPLETEDPhase 3368 miles

Low-Dose Atropine for Treatment of Myopia

NCT03334253

Study Objectives The objectives for this randomized trial are: 1. To determine the efficacy of daily low-dose atropine (0.01%) for slowing myopia progression over a two-year treatment period in children aged 5 to less than 13 years (Primary Outcome On-Treatment). 2. To determine the efficacy of atropine treatment on myopia progression 6 months following cessation of low-dose atropine treatment (Secondary Outcome Off-Treatment). Synopsis of Study Design The current study is designed as an efficacy study, making effort to maximize adherence to treatment group assignments. After a run-in phase during which all participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are updated if required) to assess their ability to adhere to daily eye drops, participants are randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off treatment.

Jaeb Center for Health Research200 participantsStarted Jun 2018

Birmingham, Alabama, United States • Atlanta, Georgia, United States • Boise, Idaho, United States +10 more locations

TERMINATEDPhase 2508 miles

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094

The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.

Atopic Dermatitis

AstraZeneca194 participantsStarted Nov 2020

Los Angeles, California, United States • Newport Beach, California, United States • Bridgeport, Connecticut, United States +48 more locations

COMPLETEDPhase 2517 miles

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00004197

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial of vaccine therapy plus sargramostim following chemotherapy in treating patients who have previously untreated aggressive non-Hodgkin's lymphoma.

University of NebraskaStarted Jun 1999

Stanford, California, United States • Omaha, Nebraska, United States

Active Not RecruitingPhase 2517 miles

High Dose IL 2 and Entinostat in RCC

NCT03501381

This is a multicenter, randomized, open label study of high dose interleukin 2 vs high dose interleukin 2 plus entinostat in clear cell RCC patients who are candidate for high dose interleukin 2. Patients will be randomized to ARM 1 (high dose interleukin 2 plus entinostat) or ARM 2 (high dose interleukin 2). Subjects will receive up to 3 courses of high dose interleukin 600,000 units/kg administered IV every 8 hrs on Days 1-5 and Days 15-19 (maximum 28 doses) +/- entinostat 5 mg orally given every 2 weeks starting on Day-14, continuously. Tumor response assessment will be performed between HD IL-2 courses.

Renal Cell Carcinoma

Roberto Pili46 participantsStarted May 2018

Los Angeles, California, United States • Chicago, Illinois, United States • Indianapolis, Indiana, United States +2 more locations

TERMINATEDPhase 2530 miles

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

NCT03919799

This randomized, placebo-controlled phase 2 study was seeking to evaluate the efficacy and safety of belumosudil (KD025) for the treatment of diffuse cutaneous systematic sclerosis. Enrolment was terminated earlier than planned for business reasons unrelated to safety. A total of 36 participants were enrolled and randomized into 3 groups to either receive orally administered belumosudil (200 milligrams \[mg\] once daily \[QD\] and 200 mg twice daily \[BID\]) or matched placebo in 1:1:1 ratio in the double-blind (DB) period of this study. Study drug dosing was for 52 weeks: double-blinded for the first 28 weeks followed by an open-label extension of 24 weeks. After unblinding, the participants on belumosudil continued on the same belumosudil dose whereas the participants in the placebo group were re-randomized to one of the belumosudil doses in a 1:1 ratio.

System; SclerosisDiffuse Cutaneous Systemic Sclerosis

Kadmon, a Sanofi Company36 participantsStarted Jun 2019

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • La Jolla, California, United States +23 more locations

COMPLETEDPhase 2539 miles

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

NCT05124275

This is a Multicenter, Randomized, Double-Masked Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia.

Glaukos Corporation123 participantsStarted Jan 2022

Chandler, Arizona, United States • Sun City, Arizona, United States • Glendale, California, United States +7 more locations

Active Not Recruiting573 miles

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

NCT00003861

This research trial studies molecular genetic features in blood and tissue samples from patients with newly diagnosed acute lymphoblastic leukemia or acute promyelocytic leukemia. Studying samples of blood and tissue from patients with acute lymphoblastic leukemia or acute promyelocytic leukemia in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

LeukemiaAcute Lymphoblastic LeukemiaAcute Promyelocytic Leukemia

Alliance for Clinical Trials in Oncology840 participantsStarted Apr 1999

San Diego, California, United States • San Francisco, California, United States • Lewes, Delaware, United States +48 more locations

TERMINATEDPhase 4625 miles

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

NCT04443608

When a patient arrives to an emergency department and is found to have an elevated potassium level in the blood, there is no one standardized treatment, therefore it is not known if one treatment is superior to other. The purpose of this study is to help determine if a drug called patiromer (already approved by the FDA) can help lower potassium levels while patients are in the emergency department.

Comprehensive Research Associates115 participantsStarted Oct 2020

Stanford, California, United States • New Haven, Connecticut, United States • Newark, Delaware, United States +16 more locations

UNKNOWN696 miles

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

NCT00900224

RATIONALE: Studying samples of tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at tissue and blood samples from patients with acute myeloid leukemia.

Alliance for Clinical Trials in Oncology529 participantsStarted Jun 2008

Mountain View, California, United States • Lewes, Delaware, United States • Newark, Delaware, United States +74 more locations

COMPLETEDPhase 2747 miles

Intermittent Hypoxia and Caffeine in Infants Born Preterm

NCT03321734

Intermittent Hypoxia and Caffeine in Infants Born Preterm (ICAF) Our proposal will address the critical question: is persisting intermittent hypoxia (IH) in preterm infants associated with biochemical, structural, or functional injury, and is this injury attenuated with extended caffeine treatment? The investigators will study the effects of caffeine on IH in 220 preterm infants born at ≤30 weeks + 6 days gestation. Infants who are currently being treated with routine caffeine, and who meet eligibility criteria, will be enrolled between 32 weeks + 0 days and 36 weeks + 6 days PMA. At enrollment, infants will be started on continuous pulse oximeter recording of O2 saturation and heart rate. If, based on standard clinical criteria, the last dose of routine caffeine is given on or before the day the infant is 36 weeks + 5 days PMA, then on the day following their last dose of routine caffeine treatment, infants will be randomized (110/group) to extended caffeine treatment or placebo. Randomized infants should begin receiving study drug (i.e. 5 mg/kg/of caffeine base, or equal volume of placebo) on the day of randomization, but no later than the third calendar day following the last dose of routine caffeine. Prior to 36 weeks + 0 days PMA, study drug will be given once daily (i.e. 5mg/kg/day) and beginning at 36 weeks + 0 days PMA, study drug will be given twice daily (i.e. 10 mg/kg/day). The last dose of study drug will be given at 42 weeks + 6 days PMA. Pulse oximeter recordings will continue 1 additional week after discontinuing study drug. Two caffeine levels will be obtained, the 1st at one week after beginning study drug, and the 2nd at a target date of 40 weeks + 0 days PMA, but no later than the last day of study drug, whether in hospital or at home. Inflammatory biomarkers will be measured at study enrollment and again at 38 weeks + 0 days PMA, or within 2 calendar days prior to hospital discharge, whichever comes first. Quantitative MRI/MRS should be obtained between study enrollment and 3 calendar days after starting study drug and again at a target date of 43 weeks + 0 days, but no later than 46 weeks + 6 days PMA.

Intermittent Hypoxia

Children's National Research Institute170 participantsStarted Jan 2019

Loma Linda, California, United States • Washington D.C., District of Columbia, United States • Orlando, Florida, United States +12 more locations

UNKNOWNPhase 1769 miles

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT05743010

This is a randomized, double-blind, placebo-controlled, phase 1b study designed to evaluate safety, tolerability, PK, and preliminary efficacy of APL-1401 in patients with moderately to severely active UC. This study comprises 3 periods including screening period (D-28\~D-1), treatment period (D1-D28), and safety follow-up period(D29-D58).

Ulcerative Colitis

Jiangsu Yahong Meditech Co., Ltd aka Asieris36 participantsStarted Jan 2023

Corona, California, United States • Tampa, Florida, United States • Marrero, Louisiana, United States +1 more locations

RECRUITING771 miles

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

NCT04131036

The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patients are on prophylactic FVIII replacement therapy intravenously several times weekly with a goal of keeping the trough \>1% FVIII. Recent phase 3 data suggest superior bleed protection with emicizumab prophylaxis every 1-2 weeks. It is the purpose of this study to longitudinally assess joint health and bone density over 3 years and to compare the effect of routine factor VIII prophylaxis with emicizumab prophylaxis.

Washington Institute for Coagulation40 participantsStarted Apr 2019

Los Angeles, California, United States • San Diego, California, United States • San Antonio, Texas, United States +1 more locations

TERMINATEDEARLY Phase 1780 miles

Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT03224819

The primary objectives of this study are to evaluate the safety and tolerability of emerfetamab in adults with relapsed/refractory acute myeloid leukemia (AML) and to estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose \[RP2D\]).

Acute Myeloid Leukemia

Amgen46 participantsStarted Sep 2017

Birmingham, Alabama, United States • Duarte, California, United States • Houston, Texas, United States +4 more locations

WITHDRAWNPhase 1/2929 miles

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

NCT04046107

The purpose of this study is to evaluate the safety and immunotherapeutic activity of cemiplimab in participants with hepatitis B virus (HBV) on suppressive antiviral therapy.

Hepatitis B Virus

National Institute of Allergy and Infectious Diseases (NIAID)Started Jan 2024

San Francisco, California, United States • Atlanta, Georgia, United States • Boston, Massachusetts, United States +5 more locations

COMPLETEDPhase 31119 miles

Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2

NCT01956123

This trial investigates the immunogenicity of FE 999049 in repeated cycles.

Ferring Pharmaceuticals513 participantsStarted Mar 2014

Brussels, Belgium • Porto Alegre, Brazil • Burnaby, British Columbia, Canada +10 more locations

PreviousPage 374 of 908Next

in Colorado

Heart Diseasein Colorado